Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
about
ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expressionNovel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer.Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.Targeted drugs for systemic therapy of lung cancer with brain metastases.
P2860
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Intermittent high-dose treatme ...... acy in EGFR-mutant lung cancer
@en
type
label
Intermittent high-dose treatme ...... acy in EGFR-mutant lung cancer
@en
prefLabel
Intermittent high-dose treatme ...... acy in EGFR-mutant lung cancer
@en
P2093
P2860
P50
P356
P1433
P1476
Intermittent high-dose treatme ...... acy in EGFR-mutant lung cancer
@en
P2093
Alexandra Florin
Caroline Volz
Dennis Plenker
Dennis Rokitta
Felix Dietlein
Jakob Schöttle
Johannes M Heuckmann
Katharina König
Kerstin Albus
Maike Siobal
P2860
P304
38458-38468
P356
10.18632/ONCOTARGET.6276
P407
P577
2015-11-02T00:00:00Z